OSIP Insider Trading Activity and SEC Form 4 Filings
OSIP insider trading summary
No open-market insider purchases or sales of Osi Pharmaceuticals Inc (OSIP) have been reported on SEC Form 4 in the past 12 months.
Latest OSIP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 7, 2010 | Astellas US Holding, Inc. | 10% Owner | Buy | $367.3M (6,387,295 @ $57.50) |
| Jun 7, 2010 | Ruby Acqusition, Inc. | 10% Owner | Buy | $367.3M (6,387,295 @ $57.50) |
| Jun 7, 2010 | Astellas Pharma Inc. | 10% Owner | Buy | $367.3M (6,387,295 @ $57.50) |
| Jun 4, 2010 | Astellas Pharma Inc. | 10% Owner | Buy | $67.6M (1,176,026 @ $57.50) |
| Jun 4, 2010 | Astellas US Holding, Inc. | 10% Owner | Buy | $67.6M (1,176,026 @ $57.50) |
| Jun 4, 2010 | Ruby Acqusition, Inc. | 10% Owner | Buy | $67.6M (1,176,026 @ $57.50) |
| Jun 1, 2010 | Angela M. Davies | Sr. VP and CMO, Oncology | Sell | $17K (298 @ $57.44) |
| Mar 1, 2010 | Linda E Amper | Sr. VP, Human Resources | Sell | $876K (15,869 @ $55.20) |
| Mar 1, 2010 | Colin Goddard | Chief Executive Officer | Sell | $3.6M (66,000 @ $55.17) |
| Mar 1, 2010 | Barbara A Wood | Sr. V.P. & General Counsel | Sell | $1.1M (20,000 @ $55.11) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.